Antiarrhythmic drug therapy after DC cardioversion of chronic atrial fibrillation - Rationale and design of the PAFAC trial;Die medikamentose prophylaxe nach elektronischer kardioversion von chronischem vorhofflimmern: Ziele und design der PAFAC-studie

Zeitschrift fur Kardiologie

Volumn 88, Issue 3, 1999, Pages 195-207

  Fetsch, T ^a   Burschel, G ^a   Breithardt, G ^a   Engberding, R ^a   Koch, H P ^a   Lukl, J ^a   Trappe, H J ^a   Treese, N ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Cardioversion; Quinidine; Sotalol; Tele ECG recording

Indexed keywords

ANTIARRHYTHMIC AGENT; CORDICHIN; QUINIDINE; SOTALOL; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AGED; ARTICLE; CARDIOVERSION; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TELEPHONE TELEMETRY; ADOLESCENT; COMPARATIVE STUDY; CZECH REPUBLIC; DRUG COMBINATION; DRUG EFFECT; ELECTROCARDIOGRAPHY; GERMANY; MIDDLE AGED; PROSPECTIVE STUDY; TELEMETRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; CZECH REPUBLIC; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINIDINE; SOTALOL; TELEMETRY; VERAPAMIL;

EID: 0032587508     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920050276     Document Type: Article

References (27)

1. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL (1990) Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 15:698-707
2. Bhandari AK, Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Cullen MTJ, Hawkinson RW, Pritchett EL (1992) Correlation of symptoms with occurrence of paroxysmal supraveturicular tachycardia or atrial fibrillation: a transtele phonic monitoring study. The Felcainide Supraventricular Tachycardia Study Group. Am Heart J 124:381-386
3. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta analysis of randomized control trials. Circulation 82:1106-1116
4. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias MD, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788
5. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L (1995) Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol 76:495-498
6. Hohnloser S, Kuck KH (1997) Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial. Pacing Clin Electrophysiol 20:1989-1992
7. Juul Moller S, Edvardsson N, Rehnqvist AN (1990) Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 82:1932-1939
8. Kalusche D, Stockinger J, Betz, P, Roskamm H (1994) Sotalol und Chinidin/Verapamil (Cordiehin) bei chronischem Vorhofflimmern Konversion und 12-Monats- Follow-up - ein randomisierter Vergleich. Z Kardiol 83, Suppl 5:109-116
9. Karlson BW, Torstensson L, Abjorn C, Jansson SO, Peterson LE (1988) Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 9:284-290
10. Klein AL, Grimm RA, Black IW, Leung DY, Chung MK, Vaughn SE, Murray RD, Miller DP, Arhcart KL (1997) Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography. Ann Intern Med 126:200-209
11. Lin HJ, Wolf PA, Kelly HM, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB (1996) Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27:1760-1764
12. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS (1995) Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 25:1354-1361
13. Moreyra E, Finkelhor RS, Cebul RD (1995) Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J 129:71-75
14. Pietersen AH, Hellemann H (1991) Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 67:713-717
15. Prystowsky EN, Benson DWJ, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG (1996) Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 93:1262-1277
16. Reimold SC, Cantillon CO, Friedman PL, Antman EM (1993) Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 71:558-563
17. Singh S, Saini RK, DiMarco J, Kluger J, Gold R, Chen YW (1991) Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. Am J Cardiol 68:1227-1230
18. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology (1994) The early termination of clinical trials: causes, consequences, and control. Circulation 89:2892-2907
19. Tebbe U, Carlsson J, Seidl K, Jansen W, Schuster HP, Elsner M, Neuhaus KL, Praetorius F (1995) Kardioversion bei Vorhofflimmern. Ergebnisse und Komplikationen bei 1152 prospektiv erfaßten Patienten. Studiengruppe der Arbeitsgemeinschaft leitender kardiologischer Kranken hausärzte (ALKK). Med Klin 90:681-687
20. The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227-233
21. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators (1997) Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM study design. Am J Cardiol 79:1198-1202
22. The Stroke Prevention in Atrial Fibrillation Investigators (1992) Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 116:1-5
23. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348:7-12
24. Wolf PA, Abbott RD, Kannel WB (1987) Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 147:1561-1564
25. Wolf PA, Abbott RD, Kannel WB (1990) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983-988
26. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB (1978) Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 28:973-977
27. Zehender M, Hohnloser S, Muller B, Meinertz T, Just H (1992) Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 19:1054-1059